Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), said there is nevertheless no getting away from the fact that the package reduces ...

The new data comes from the KEYLYNK-001 study evaluating Keytruda (pembrolizumab) and chemotherapy followed by Lynparza (olaparib) maintenance therapy with or without bevacizumab in patients with ...